Results 141 to 150 of about 129,216 (298)

Multimodal Actuation and Environment Adaptive Strategies of Bio‐Inspired Micro/Nanorobots in Precision Medicine

Advanced Robotics Research, EarlyView.
An introduction for multidrive and environment‐adaptive micro/nanorobotics: design and fabrication strategies, intelligent actuation, and their applications. Various intelligent actuation approaches—magnetic, acoustic, optical, chemical, and biological—can be synergistically designed to enhance flexibility and adaptive behavior for precision medicine ...
Aiqing Ma, Han Gong, Jiacheng Ouyang, Liqi Chen, Tianfang Kang, Yiran He, Guojun Huang, Sidi Zheng, Ting Yin, Hong Pan, Lintao Cai   +10 more
wiley   +1 more source

CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity

Frontiers in Immunology
IntroductionImmunogenic cell death (ICD) has emerged as a novel option for cancer immunotherapy. The key determinants of ICD encompass antigenicity (the presence of antigens) and adjuvanticity, which involves the release of damage-associated molecular ...
Faye Naessens, Faye Naessens, Robin Demuynck, Robin Demuynck, Olga Vershinina, Iuliia Efimova, Iuliia Efimova, Mariia Saviuk, Mariia Saviuk, Greet De Smet, Tatiana A. Mishchenko, Maria V. Vedunova, Olga Krysko, Elena Catanzaro, Elena Catanzaro, Dmitri V. Krysko, Dmitri V. Krysko   +16 more
doaj   +1 more source

Annus Mirabilis - a guide to the 6th European Lupus meeting 3-5 March 2005 [PDF]

, 2005
This article has no ...
Bowman, S.J., Giles, I.P., Ioannou, Y., Isenburg, D.A., Rahman, A.   +4 more
core  

Magnetic Micro‐ and Nanorobots for Precision Thrombolysis: Design Strategies and Translational Challenges

Advanced Robotics Research, EarlyView.
Micro‐ and nanorobots for targeted thrombolysis. This perspective elaborates on the clinical indication of blood clot disorders and current limitations for treatment. As a novel, alternative solution, micro‐ and nanorobots can be used to treat and break down thrombi.
Joshua M. Mesfin, Yimo Yan, Nikola Cesarovic, Simone Schuerle   +3 more
wiley   +1 more source

RIG‐I Mediated Neuron‐Specific IFN Type 1 Signaling in FUS‐ALS Induces Neurodegeneration and Offers New Biomarker‐Driven Individualized Treatment Options for (FUS‐)ALS

Advanced Science, EarlyView.
Using iPSC‐derived motoneurons and postmortem tissue from FUS‐ALS patients, it is demonstrated that increased mitochondrial transcription leads to elevated cytosolic double‐stranded RNA (dsRNA) levels. This aberrant accumulation activates a RIG‐I–dependent innate immune response leading to neurodegeneration, which is amenable for FDA‐ and EMA‐approved ...
Marcel Naumann, Theresa M. Wierschin, Stefanie Kretschmer, Banaja P. Dash, Aaron Held, Andrea Salzinger, Kevin Peikert, Anže Karlek, Hannes Glaß, Dajana Großmann, René Günther, Susanne Petri, Annekathrin Rödiger, David Brenner, Francisco Pan‐Montojo, Eleonora Aronica, Markus Kipp, Vitaly Zimyanin, Jared Sterneckert, Torsten Grehl, Noah D. Seebacher, Tobias M. Böckers, Alberto Catanese, Brian J. Wainger, Patrick Oeckl, Min Ae Lee‐Kirsch, Andreas Hermann   +26 more
wiley   +1 more source

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. [PDF]

, 2019
Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to ...
Adashek, Jacob J, Galanina, Natalie, Junior, Pedro Nazareth Aguiar, Kurzrock, Razelle   +3 more
core  

CypD Dependent mPTP Opening Is Crucial for Oxidized Mitochondrial DNA Release in Ferroptosis

Advanced Science, EarlyView.
Ferroptosis is driven by mitochondrial permeability transition pore (mPTP) opening, which induces mitochondrial swelling and releases oxidized mitochondrial DNA. The released mtDNA activates cGAS–STING signaling, promotes ferritinophagy, and amplifies ferroptotic cell death. Disruption of mtDNA repair sensitizes tumors to ferroptosis in vivo, revealing
Hong Zhou, Wan Fu, Shizuo Liu, Zili Zhang, Hanyan Luo, Qing Zhong   +5 more
wiley   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Astrocyte Enrichment of 3D Cortical Constructs Enhances Brain Repair

Advanced Science, EarlyView.
This study highlights the role of astrocytes in supporting neural progenitor cell survival and differentiation after traumatic brain injury. Astrocytes enhanced neuronal differentiation, improved cell survival in co‐cultures, and promoted integration of microfluidics‐based implants with host tissue following implantation. Additionally, increased axonal
Elisa M. Cruz, Luana C. Soares, Gretchen Greene, Fernando Messore, Mohammed Abuelem, Mingyu Li, Caroline Andersen, Mirriam Domocos, Elisa Vitiello, Rabeah Abdul Razak, Marlene Lawston, Gabriel Moser, Talia Vasaturo‐Kolodner, Mona Barkat, Roslyn M. Bill, Edward Mann, Linna Zhou, Mootaz M. Salman, Hagan Bayley, Zoltán Molnár, Francis G. Szele   +20 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source